Familial hypercholesterolemia (FH) is a hereditary condition caused by mutations in the lipid
pathway. The goal in managing FH is to reduce circulating low‐density lipoprotein …

Patients with familial hypercholesterolemia (FH) are likely at increased risk for COVID-19
complications in the acute phase of the infection, and for a long time thereafter. Because in …

A recent meta-analysis of over 20,000 individuals showed that hospitalized COVID-19
patients with acute myocardial injury had more than fourfold higher mortality than those …

Abstract Individuals with Familial Hypercholesterolaemia (FH) are at very high risk of
cardiovascular disease, which is associated with poor outcomes from coronavirus infections …

We respectfully submit this letter in response to the May 2021 article “COVID-19 associated
risks of myocardial infarction in persons with familial hypercholesterolemia with or without …

The sudden outbreak of coronavirus disease 2019 (COVID-19) caused unprecedented
pressure on the community and the national health systems. 1, 2 The irrepressible …

The importance of dyslipidemia medications in patients with coronavirus disease 2019
(COVID-19) is currently not sufficiently recognized in the prevention of thrombotic events. 1 …

Heterozygous familial hypercholesterolemia (HeFH) patients are the prime example of
subjects who are at high risk for both acute myocardial infarction (AMI) and ischemic stroke …

Cardiovascular disease (CVD), hypertension, and heart failure are associated with higher
rates of coronavirus disease 2019 (COVID-19) related morbidity and mortality [1, 2] …

We evaluated the impact of direct and indirect effects of SARS-CoV-2 infection in subjects
with familial hypercholesterolemia (FH). In this observational, retrospective study, 260 FH …